Miridesap (Ro 638695, GSK-2315698, CPHPC) is a competitive inhibitor of serum amyloid P component (SAP) binding to amyloid fibrils.
Miridesap crosslinks and dimerizes SAP molecules, leading to their very rapid clearance by the liver, and thus produces a marked depletion of circulating human SAP.
Miridesap is a novel therapeutic approach to both systemic amyloidosis and diseases associated with local amyloid, including Alzheimer's disease and type 2 diabetes.
Physicochemical Properties
M.Wt
340.376
Formula
C16H24N2O6
Appearance
Solid
CAS No.
Storage
Solide Powder
-20 °C 12 Months; 4°C 6 Months
In Solvent
-80 °C 6 Months; -20°C 6 Months
Shipping
Solubility
10 mM in DMSO
Chemical Name/SMILES
1,1'-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
References
1. Kolstoe SE, et al. Proc Natl Acad Sci U S A. 2009 May 5;106(18):7619-23.
2. Pepys MB, et al. Nature. 2002 May 16;417(6886):254-9.
